Inferior vena cava filters: Concept review and summary of current guidelines
Vascul Pharmacol. 2024 Apr 23:107375. doi: 10.1016/j.vph.2024.107375. Online ahead of print.ABSTRACTAnticoagulation is the first-line approach in the prevention and treatment of pulmonary embolism. In some instances, however, anticoagulation fails, or cannot be administered due to a high risk of bleeding. Inferior vena cava filters are metal alloy devices that mechanically trap emboli from the deep leg veins halting their transit to the pulmonary circulation, thus providing a mechanical alternative to anticoagulation in such conditions. The Greenfield filter was developed in 1973 and was later perfected to a model that cou...
Source: Vascular Pharmacology - April 25, 2024 Category: Drugs & Pharmacology Authors: Luca Visconti Alessandro Celi Laura Carrozzi Camilla Tinelli Laura Crocetti Francesco Daviddi Raffaele De Caterina Rosalinda Madonna Roberta Pancani Source Type: research
Inferior vena cava filters: Concept review and summary of current guidelines
Vascul Pharmacol. 2024 Apr 23:107375. doi: 10.1016/j.vph.2024.107375. Online ahead of print.ABSTRACTAnticoagulation is the first-line approach in the prevention and treatment of pulmonary embolism. In some instances, however, anticoagulation fails, or cannot be administered due to a high risk of bleeding. Inferior vena cava filters are metal alloy devices that mechanically trap emboli from the deep leg veins halting their transit to the pulmonary circulation, thus providing a mechanical alternative to anticoagulation in such conditions. The Greenfield filter was developed in 1973 and was later perfected to a model that cou...
Source: Vascular Pharmacology - April 25, 2024 Category: Drugs & Pharmacology Authors: Luca Visconti Alessandro Celi Laura Carrozzi Camilla Tinelli Laura Crocetti Francesco Daviddi Raffaele De Caterina Rosalinda Madonna Roberta Pancani Source Type: research
Inferior vena cava filters: Concept review and summary of current guidelines
Vascul Pharmacol. 2024 Apr 23:107375. doi: 10.1016/j.vph.2024.107375. Online ahead of print.ABSTRACTAnticoagulation is the first-line approach in the prevention and treatment of pulmonary embolism. In some instances, however, anticoagulation fails, or cannot be administered due to a high risk of bleeding. Inferior vena cava filters are metal alloy devices that mechanically trap emboli from the deep leg veins halting their transit to the pulmonary circulation, thus providing a mechanical alternative to anticoagulation in such conditions. The Greenfield filter was developed in 1973 and was later perfected to a model that cou...
Source: Vascular Pharmacology - April 25, 2024 Category: Drugs & Pharmacology Authors: Luca Visconti Alessandro Celi Laura Carrozzi Camilla Tinelli Laura Crocetti Francesco Daviddi Raffaele De Caterina Rosalinda Madonna Roberta Pancani Source Type: research
Inferior vena cava filters: Concept review and summary of current guidelines
Vascul Pharmacol. 2024 Apr 23:107375. doi: 10.1016/j.vph.2024.107375. Online ahead of print.ABSTRACTAnticoagulation is the first-line approach in the prevention and treatment of pulmonary embolism. In some instances, however, anticoagulation fails, or cannot be administered due to a high risk of bleeding. Inferior vena cava filters are metal alloy devices that mechanically trap emboli from the deep leg veins halting their transit to the pulmonary circulation, thus providing a mechanical alternative to anticoagulation in such conditions. The Greenfield filter was developed in 1973 and was later perfected to a model that cou...
Source: Vascular Pharmacology - April 25, 2024 Category: Drugs & Pharmacology Authors: Luca Visconti Alessandro Celi Laura Carrozzi Camilla Tinelli Laura Crocetti Francesco Daviddi Raffaele De Caterina Rosalinda Madonna Roberta Pancani Source Type: research
Corrigendum to "Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis" [Vascular Pharmacology 155 (2024) 107368]
Vascul Pharmacol. 2024 Apr 23:107373. doi: 10.1016/j.vph.2024.107373. Online ahead of print.NO ABSTRACTPMID:38658307 | DOI:10.1016/j.vph.2024.107373 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - April 24, 2024 Category: Drugs & Pharmacology Authors: Bandana Singh Kui Cui Shahram Eisa-Beygi Bo Zhu Douglas B Cowan Jinjun Shi Chris A Bashur Da-Zhi Wang Zhenguo Liu Joyce Bischoff Hong Chen Source Type: research
Corrigendum to "Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis" [Vascular Pharmacology 155 (2024) 107368]
Vascul Pharmacol. 2024 Apr 23:107373. doi: 10.1016/j.vph.2024.107373. Online ahead of print.NO ABSTRACTPMID:38658307 | DOI:10.1016/j.vph.2024.107373 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - April 24, 2024 Category: Drugs & Pharmacology Authors: Bandana Singh Kui Cui Shahram Eisa-Beygi Bo Zhu Douglas B Cowan Jinjun Shi Chris A Bashur Da-Zhi Wang Zhenguo Liu Joyce Bischoff Hong Chen Source Type: research
Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC/ERS 2022 guidelines
Vascul Pharmacol. 2024 Apr 18;155:107374. doi: 10.1016/j.vph.2024.107374. Online ahead of print.ABSTRACTA comprehensive evaluation of risk, using multiple indices, is necessary to provide reliable prognostic information and guide therapy in pulmonary arterial hypertension (PAH). The current ESC/ERS guidelines suggest using a three-strata model for incident (newly diagnosed) patients and a four-strata model for prevalent patients with PAH. The four-strata model serves as a fundamental risk-stratification tool and relies on a minimal dataset of indicators that must be considered during follow-up. Nevertheless, there are stil...
Source: Vascular Pharmacology - April 20, 2024 Category: Drugs & Pharmacology Authors: Michele D'Alto Roberto Badagliacca Edoardo Air ò Pietro Ameri Paola Argiento Andrea Garascia Carlo Mario Lombardi Massimiliano Mul è Claudia Raineri Laura Scelsi Carmine Dario Vizza Stefano Ghio Source Type: research
Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC/ERS 2022 guidelines
Vascul Pharmacol. 2024 Apr 18;155:107374. doi: 10.1016/j.vph.2024.107374. Online ahead of print.ABSTRACTA comprehensive evaluation of risk, using multiple indices, is necessary to provide reliable prognostic information and guide therapy in pulmonary arterial hypertension (PAH). The current ESC/ERS guidelines suggest using a three-strata model for incident (newly diagnosed) patients and a four-strata model for prevalent patients with PAH. The four-strata model serves as a fundamental risk-stratification tool and relies on a minimal dataset of indicators that must be considered during follow-up. Nevertheless, there are stil...
Source: Vascular Pharmacology - April 20, 2024 Category: Drugs & Pharmacology Authors: Michele D'Alto Roberto Badagliacca Edoardo Air ò Pietro Ameri Paola Argiento Andrea Garascia Carlo Mario Lombardi Massimiliano Mul è Claudia Raineri Laura Scelsi Carmine Dario Vizza Stefano Ghio Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferati...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferati...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
